As we see the potential benefits of both SGLT2 inhibitors and pioglitazone, we believe that a systematic review is called for to critically evaluate the existing evidence and also compare the efficacy of these two drugs in treating NAFLD/NASH. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.